Rechallenge Therapy: New Dimensions in Cancer Therapy

The evolution of resistance to different types of cancer therapies has become a significant challenge in oncology research, leading to disease progression and limited treatment options. Rechallenge therapy, where a previously used treatment is reintroduced after a period of discontinuation, has emerged as a potential strategy to overcome resistance.

This review synthesizes current knowledge on rechallenge therapy by analyzing data from clinical trials, retrospective studies, and case reports. A comprehensive examination was conducted across multiple cancer types and therapeutic classes, including immunotherapy, chemotherapy, targeted therapy, hormonal therapy, and combination approaches.

The efficacy of rechallenge therapy varies across cancer types. For instance, in metastatic colorectal cancer, anti-EGFR rechallenge therapy has shown response rates of 20-30% in RAS wild-type patients after a drug-free interval. In prostate cancer, rechallenge with androgen deprivation therapy or abiraterone has demonstrated biochemical response rates of approximately 30-40% in selected populations.

In hormone receptor-positive breast cancer, endocrine therapy rechallenges, especially following a treatment break, have yielded clinical benefit rates of over 40% in some cohorts. These outcomes are influenced by tumor biology, duration of prior response, molecular profiling, and patient selection criteria.

Rechallenge approaches show promise as viable options for treating cancer recurrence and resistance, but their application must be carefully tailored to each patient. A well-planned scientific strategy is required to optimize different rechallenge approaches, identify predictive biomarkers, and understand the longterm outcomes associated with this method.